Leerink Partnrs Has Bearish Forecast for RCUS Q1 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for Arcus Biosciences in a research note issued on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings of ($1.13) per share for the quarter, down from their previous forecast of ($0.89). The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences' Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.41) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($1.72) EPS and FY2028 earnings at $1.06 EPS.

Several other research firms have also recently weighed in on RCUS. Bank of America decreased their target price on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Morgan Stanley reduced their price objective on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Finally, HC Wainwright upgraded Arcus Biosciences from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $18.00 to $24.00 in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $30.25.

Arcus Biosciences Stock Down 3.3 %

RCUS stock traded down $0.36 during trading on Friday, hitting $10.53. 1,116,764 shares of the company's stock were exchanged, compared to its average volume of 705,185. The business has a 50-day moving average price of $13.26 and a two-hundred day moving average price of $15.36. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -3.34 and a beta of 0.84. Arcus Biosciences has a 52-week low of $9.86 and a 52-week high of $19.69. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. The firm had revenue of $36.00 million during the quarter, compared to analysts' expectations of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP grew its holdings in Arcus Biosciences by 17.8% in the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company's stock valued at $2,866,000 after purchasing an additional 28,307 shares during the last quarter. Quest Partners LLC grew its holdings in Arcus Biosciences by 40,904.3% in the third quarter. Quest Partners LLC now owns 9,431 shares of the company's stock valued at $144,000 after purchasing an additional 9,408 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Arcus Biosciences by 25.1% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company's stock valued at $14,236,000 after purchasing an additional 186,750 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Arcus Biosciences during the third quarter valued at $244,000. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Arcus Biosciences by 39.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 80,889 shares of the company's stock valued at $1,237,000 after acquiring an additional 22,716 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.

Insider Transactions at Arcus Biosciences

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the company's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares of the company's stock, valued at $902,070. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Yasunori Kaneko acquired 20,000 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the acquisition, the director now directly owns 28,400 shares of the company's stock, valued at $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.